Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

US9932613B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9932613-B2
Application numberUS-201715792446-A
CountryUS
Kind codeB2
Filing dateOct 24, 2017
Priority dateMay 11, 2012
Publication dateApr 3, 2018
Grant dateApr 3, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

First claim

Opening claim text (preview).

What is claimed is: 1. An engineered polynucleotide encoding an engineered polypeptide having imine reductase activity, wherein said polypeptide has at least 90% sequence identity to the polypeptide of SEQ ID NO: 2, and comprises a substitution at a position corresponding to position 280 of SEQ ID NO: 2, wherein the amino acid at position 280 has been replaced with an aliphatic or non-polar residue. 2. The engineered polynucleotide of claim 1 , wherein said polypeptide has at least 90% sequence identity to the polypeptide of SEQ ID NO: 2, wherein the amino acid at the position corresponding to position 280 of SEQ ID NO: 2 has been replaced with leucine. 3. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1a) pyruvate, and substrate compound (2b) butylamine to product compound (3b), N-2-(butylamino)propanoic acid, under suitable reaction conditions. 4. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2a) L-norvaline to product compound (3c), (S)-2-(cyclohexylamino)pentanoic acid, under suitable reaction conditions. 5. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2b) butylamine to product compound (3d), N-butylcyclohexanamine, under suitable reaction conditions. 6. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1i), and substrate compound (2b) to product compound (3n), under suitable reaction conditions. 7. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1j), and substrate compound (2b) to product compound (3o), under suitable reaction conditions.

Assignees

Inventors

Classifications

  • Amines; Imines · CPC title

  • Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system (cepam nucleus C12P35/00; penam nucleus C12P37/00) · CPC title

  • C12P13/02Primary

    Amides, e.g. chloramphenicol {or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes (peptides C12P21/00 or C07K)} · CPC title

  • Alanine; Leucine; Isoleucine; Serine; Homoserine · CPC title

  • Tauropine dehydrogenase (1.5.1.23) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9932613B2 cover?
The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Who is the assignee on this patent?
Codexis Inc
What technology area does this patent fall under?
Primary CPC classification C12P13/02. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).